A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. An experimental vaccine ...

• One dose of RBX2660 followed by one dose of placebo — Group C The researchers defined efficacy as prevention of recurrent C. diff for eight weeks following treatment. The overall efficacy for ...

Community exposure to the superbug Clostridiodes difficile may be more common than previously thought, with a surprising amount of spores carried on the soles of shoes, a new study has found. C. diff ...

C. diff is a type of bacteria that can cause diarrhea, abdominal pain, and tenderness. It is commonly treated with antibiotics such as fidaxomicin (Dificid) and vancomycin (Firvanq). C. diff, short ...

What are the characteristics of C. difficile infection? Clostridium difficile is a Gram-positive bacterium that induces inflammation in the intestine via two toxins, namely TcdA and TcdB. A variety of ...

Recurrent C. diff infection is when you contract a C. diff infection 2 to 8 weeks after completing treatment for a previous one. C. diff relapse is a recurrence of the same strain, while reinfection ...